DK1617834T3 - Anvendelse af en farmaceutisk sammensætning indeholdende mælkesyre eller lactat og kalium til behandling af hjerneödem eller hjerneskade - Google Patents

Anvendelse af en farmaceutisk sammensætning indeholdende mælkesyre eller lactat og kalium til behandling af hjerneödem eller hjerneskade

Info

Publication number: DK1617834T3
Authority: DK; Denmark
Prior art keywords: brain; lactate; potassium; treatment; pharmaceutical composition
Prior art date: 2003-05-01

Application number

DK04722501T

Other languages

English (en)

Inventor

Xavier M Leverve

Mustafa Iqbal

Original Assignee

Innogene Kalbiotech Pte Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-01

Filing date

2004-03-22

Publication date

2007-02-05

2004-03-22 Application filed by Innogene Kalbiotech Pte Ltd filed Critical Innogene Kalbiotech Pte Ltd

2007-02-05 Application granted granted Critical

2007-02-05 Publication of DK1617834T3 publication Critical patent/DK1617834T3/da

Links

JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title 2
206010048962 Brain oedema Diseases 0.000 title 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 title 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title 1
230000006931 brain damage Effects 0.000 title 1
231100000874 brain damage Toxicity 0.000 title 1
208000006752 brain edema Diseases 0.000 title 1
208000029028 brain injury Diseases 0.000 title 1
235000014655 lactic acid Nutrition 0.000 title 1
239000004310 lactic acid Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
229910052700 potassium Inorganic materials 0.000 title 1
239000011591 potassium Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Inorganic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Mycology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Nutrition Science (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Child & Adolescent Psychology (AREA)

DK04722501T 2003-05-01 2004-03-22 Anvendelse af en farmaceutisk sammensætning indeholdende mælkesyre eller lactat og kalium til behandling af hjerneödem eller hjerneskade DK1617834T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ID20030213		2003-05-01
PCT/SG2004/000066 WO2004096204A1 (en)	2003-05-01	2004-03-22	Lactate containing pharmaceutical composition and uses thereof

Publications (1)

Publication Number	Publication Date
DK1617834T3 true DK1617834T3 (da)	2007-02-05

Family

ID=33397627

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04722501T DK1617834T3 (da)	2003-05-01	2004-03-22	Anvendelse af en farmaceutisk sammensætning indeholdende mælkesyre eller lactat og kalium til behandling af hjerneödem eller hjerneskade

Country Status (30)

Country	Link
US (1)	US20080125488A1 (da)
EP (2)	EP1759695A1 (da)
JP (1)	JP5037937B2 (da)
KR (1)	KR101076059B1 (da)
CN (1)	CN1777416B (da)
AR (1)	AR043670A1 (da)
AT (1)	ATE340568T1 (da)
AU (1)	AU2004233904B2 (da)
BR (1)	BRPI0409867A (da)
CA (1)	CA2523740C (da)
CY (1)	CY1105880T1 (da)
DE (1)	DE602004002585T2 (da)
DK (1)	DK1617834T3 (da)
EA (2)	EA013846B1 (da)
ES (1)	ES2274438T3 (da)
IL (1)	IL171721A (da)
MA (1)	MA27845A1 (da)
MX (1)	MXPA05011532A (da)
MY (1)	MY140382A (da)
NO (1)	NO20055652L (da)
NZ (1)	NZ543201A (da)
PL (1)	PL1617834T3 (da)
PT (1)	PT1617834E (da)
SG (1)	SG160217A1 (da)
SI (1)	SI1617834T1 (da)
TN (1)	TNSN05275A1 (da)
TW (1)	TWI290045B (da)
UA (1)	UA86937C2 (da)
WO (1)	WO2004096204A1 (da)
ZA (1)	ZA200509684B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2007371A4 (en) *	2006-04-03	2009-07-22	Innogene Kalbiotech Pte Ltd	LACTAT AND CALCIUM-CONTAINED PHARMACEUTICAL COMPOSITION AND ITS USES
BRPI0809330B8 (pt)	2007-03-30	2021-05-25	Laccure Ab	uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica
KR20120015295A (ko) *	2009-03-26	2012-02-21	풀매트릭스 인코퍼레이티드	점막 내층의 생물물리학적 성질의 변경을 위한 구연산 칼슘 및 젖산 칼슘 제형
JP5671001B2 (ja)	2009-03-26	2015-02-18	パルマトリックス，インコーポレイテッド	肺疾患を治療するための乾燥粉末製剤および方法
WO2012030664A1 (en)	2010-08-30	2012-03-08	Pulmatrix, Inc.	Dry powder formulations and methods for treating pulmonary diseases
US8758824B2 (en)	2010-08-30	2014-06-24	Pulmatrix, Inc.	Respirably dry powder comprising calcium lactate, sodium chloride and leucine
EP4008326A1 (en)	2010-09-29	2022-06-08	Pulmatrix Operating Company, Inc.	Monovalent metal cation dry powders for inhalation
PT2621488T (pt)	2010-09-29	2019-02-12	Pulmatrix Operating Co Inc	Pós secos catiónicos
ES2396650B2 (es) *	2011-07-21	2013-07-16	Universidad Complutense De Madrid	Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
US20150136130A1 (en)	2012-02-29	2015-05-21	Pulmatrix, Inc.	Inhalable dry powders
CN104602682B (zh)	2012-05-08	2018-12-14	埃罗米克斯公司	用于治疗水通道蛋白介导的疾病的化合物
ES2604855T3 (es) *	2012-08-01	2017-03-09	Purac Biochem Bv	Polvo de lactato y procedimiento de preparación del mismo
US9232815B2 (en)	2012-10-25	2016-01-12	Run Them Sweet, LLC	Blood lactate range targets and nutritional formulations and protocols to support patients
US9897609B2 (en)	2012-10-25	2018-02-20	Run Them Sweet, LLC	Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
US9557334B2 (en)	2012-10-25	2017-01-31	Run Them Sweet Llc	Formulations and methods to provide nutrition to human and other patients
EP2754356A1 (en)	2013-01-15	2014-07-16	Purac Biochem N.V.	Improved nisin production process
EP2769630B1 (en)	2013-02-26	2016-04-27	Purac Biochem N.V.	Improved nisin production process
KR20150135328A (ko)	2013-04-01	2015-12-02	풀매트릭스 인코퍼레이티드	티오트로피움 건조 분말
EP3065729A4 (en)	2013-11-06	2017-05-31	Aeromics, Inc.	Novel formulations
WO2015182815A1 (ko) *	2014-05-26	2015-12-03	한국생명공학연구원	Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물
EP3481216B2 (en)	2016-07-07	2024-03-06	DSM IP Assets B.V.	Process for obtaining a rapeseed protein isolate and protein isolate thereby obtained
US10124021B2 (en) *	2016-12-23	2018-11-13	Andrew L. Gostine	Intravenous fluid
EP3920846A4 (en) *	2019-02-06	2022-11-09	The Board and Trustees of the Leland Stanford Junior University	BIOLOGICALLY MODIFIED VASCULAR GRAPES FOR IMPROVED OUTCOMES IN BYPASS SURGERY
US20230113843A1 (en) *	2020-01-24	2023-04-13	Daniel Q. Barkey	Compositions and methods for weight loss
CN119013010A (zh) *	2021-12-16	2024-11-22	艾维尔勒斯生物公司	用于治疗慢性肺病的可吸入或可摄入的乳酸组合物
CN116531358A (zh) *	2023-06-06	2023-08-04	中国医科大学附属第一医院	含乳酸盐缓冲体系在制备心力衰竭治疗药物中的应用
EP4502147A1 (en)	2023-07-31	2025-02-05	M2Rlab SL	Method for the polarization of cells to a new m2 phenotype and uses of said m2-polarized cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS63502274A (ja) *	1985-12-18	1988-09-01	ビ−チ，リチヤ−ド　エル	Ｌ↓−乳酸および／またはピルビン酸アニオンを用いた流体式治療法
EP0441119A3 (en) *	1990-01-09	1992-10-14	Richard D. Levere	The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) *	1991-05-31	1993-09-28	Board Of Regents, The University Of Texas System	Hypertonic isochloremic formulation for circulatory shock
JPH05255092A (ja) *	1992-03-17	1993-10-05	Kyowa Hakko Kogyo Co Ltd	腸管洗浄用組成物
PT701455E (pt) *	1993-06-04	2001-09-27	Biotime Inc	Solucao semelhante a plasma
US6306828B1 (en) *	1995-04-06	2001-10-23	Baxter International, Inc.	Enantiomerically-enhanced nutritional energy substrates
JPH0940554A (ja) *	1995-08-03	1997-02-10	Nissho Corp	グルタミンを含む輸液及びその製造方法
WO1998008500A1 (en) *	1996-08-26	1998-03-05	Board Of Regents, The University Of Texas System	Hypertonic arginine compositions and methods
US6436444B1 (en) *	1997-09-26	2002-08-20	Ecolab Inc.	Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
CN1068778C (zh) *	1998-05-15	2001-07-25	赵超英	救治用的药物组合物及其制备方法
RU2136293C1 (ru) *	1998-08-04	1999-09-10	Открытое акционерное общество "Биохимик"	Способ получения заменителя плазмы крови

2004
- 2004-03-22 SI SI200430136T patent/SI1617834T1/sl unknown
- 2004-03-22 NZ NZ543201A patent/NZ543201A/en not_active IP Right Cessation
- 2004-03-22 DK DK04722501T patent/DK1617834T3/da active
- 2004-03-22 PL PL04722501T patent/PL1617834T3/pl unknown
- 2004-03-22 EP EP06121128A patent/EP1759695A1/en not_active Withdrawn
- 2004-03-22 PT PT04722501T patent/PT1617834E/pt unknown
- 2004-03-22 CN CN2004800110612A patent/CN1777416B/zh not_active Expired - Fee Related
- 2004-03-22 AT AT04722501T patent/ATE340568T1/de active
- 2004-03-22 UA UAA200511417A patent/UA86937C2/ru unknown
- 2004-03-22 AU AU2004233904A patent/AU2004233904B2/en not_active Ceased
- 2004-03-22 DE DE602004002585T patent/DE602004002585T2/de not_active Expired - Lifetime
- 2004-03-22 WO PCT/SG2004/000066 patent/WO2004096204A1/en not_active Ceased
- 2004-03-22 EA EA200801073A patent/EA013846B1/ru not_active IP Right Cessation
- 2004-03-22 AR ARP040100933A patent/AR043670A1/es not_active Application Discontinuation
- 2004-03-22 MY MYPI20040998A patent/MY140382A/en unknown
- 2004-03-22 CA CA2523740A patent/CA2523740C/en not_active Expired - Fee Related
- 2004-03-22 BR BRPI0409867-6A patent/BRPI0409867A/pt not_active IP Right Cessation
- 2004-03-22 EP EP04722501A patent/EP1617834B1/en not_active Expired - Lifetime
- 2004-03-22 ES ES04722501T patent/ES2274438T3/es not_active Expired - Lifetime
- 2004-03-22 US US10/555,196 patent/US20080125488A1/en not_active Abandoned
- 2004-03-22 EA EA200501675A patent/EA010948B1/ru not_active IP Right Cessation
- 2004-03-22 SG SG200717319-8A patent/SG160217A1/en unknown
- 2004-03-22 JP JP2006508059A patent/JP5037937B2/ja not_active Expired - Fee Related
- 2004-03-22 MX MXPA05011532A patent/MXPA05011532A/es active IP Right Grant
- 2004-03-22 KR KR1020057020706A patent/KR101076059B1/ko not_active Expired - Fee Related
- 2004-03-23 TW TW093107705A patent/TWI290045B/zh not_active IP Right Cessation
2005
- 2005-10-24 TN TNP2005000275A patent/TNSN05275A1/en unknown
- 2005-11-01 IL IL171721A patent/IL171721A/en active IP Right Grant
- 2005-11-30 ZA ZA200509684A patent/ZA200509684B/en unknown
- 2005-11-30 NO NO20055652A patent/NO20055652L/no not_active Application Discontinuation
- 2005-12-01 MA MA28632A patent/MA27845A1/fr unknown
2006
- 2006-12-21 CY CY20061101847T patent/CY1105880T1/el unknown

Also Published As

Publication number	Publication date
PL1617834T3 (pl)	2007-02-28
TWI290045B (en)	2007-11-21
NO20055652D0 (no)	2005-11-30
JP5037937B2 (ja)	2012-10-03
KR20050119701A (ko)	2005-12-21
SG160217A1 (en)	2010-04-29
EP1617834A1 (en)	2006-01-25
TW200423923A (en)	2004-11-16
HK1085942A1 (en)	2006-09-08
IL171721A (en)	2012-05-31
AU2004233904A1 (en)	2004-11-11
CN1777416B (zh)	2012-11-07
EA013846B1 (ru)	2010-08-30
TNSN05275A1 (en)	2007-07-10
NZ543201A (en)	2007-05-31
MXPA05011532A (es)	2006-05-31
KR101076059B1 (ko)	2011-10-21
ATE340568T1 (de)	2006-10-15
WO2004096204A1 (en)	2004-11-11
CN1777416A (zh)	2006-05-24
ZA200509684B (en)	2007-03-28
DE602004002585D1 (de)	2006-11-09
BRPI0409867A (pt)	2006-05-16
EP1759695A1 (en)	2007-03-07
SI1617834T1 (sl)	2007-02-28
US20080125488A1 (en)	2008-05-29
ES2274438T3 (es)	2007-05-16
CA2523740A1 (en)	2004-11-11
MY140382A (en)	2009-12-31
EA200801073A1 (ru)	2008-08-29
CA2523740C (en)	2012-05-15
AU2004233904B2 (en)	2009-11-12
UA86937C2 (ru)	2009-06-10
JP2006525324A (ja)	2006-11-09
EP1617834B1 (en)	2006-09-27
PT1617834E (pt)	2007-01-31
EA200501675A1 (ru)	2006-06-30
AR043670A1 (es)	2005-08-03
NO20055652L (no)	2006-02-01
MA27845A1 (fr)	2006-04-03
EA010948B1 (ru)	2008-12-30
CY1105880T1 (el)	2011-02-02
DE602004002585T2 (de)	2007-10-25

Publication	Publication Date	Title
DK1853271T3 (da)	2011-01-24	Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DE602005026984D1 (de)	2011-04-28	Chinolin-derivate zur behandlung von latenter tuberkulose
IS8142A (is)	2005-11-23	Læknislyf gagnleg til meðferðar á verkjum
DK1487541T3 (da)	2009-01-19	Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
DK3889142T3 (da)	2022-09-12	1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsense-suppression og behandling af sygdom
EP1758597A4 (en)	2008-02-27	USE OF MEDICINAL COMBINATIONS FOR TREATING INSULIN RESISTANCE
EP1755661A4 (en)	2008-02-20	USE OF GELSOLIN FOR THE TREATMENT OF INFECTIONS
DE602005005810D1 (de)	2008-05-15	Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE512163T1 (de)	2011-06-15	Verabreichung von mitteln zur behandlung von entzündungen
DE602004002585D1 (de)	2006-11-09	VERWENDUNG EINER PHARMAZEUTISCHEN FORMULIERUNG ENTHALTEND MILCHSÄURE ODER LAKTAT UND kALIUM ZUR BEHANDLUNG VON HIRNÖDEM UND VERLETZUNGEN DES GEHIRNS
EP1851237A4 (en)	2009-01-07	PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF BONE DISEASES
EP1742675A4 (en)	2008-09-10	TREATMENT OF BIOMEDICAL WASTE
ATE476414T1 (de)	2010-08-15	Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
CY2018006I2 (el)	2018-06-27	Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
DE602005017503D1 (de)	2009-12-17	Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE438623T1 (de)	2009-08-15	Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
PT1781298E (pt)	2012-02-03	Combinações farmacêuticas contendo benzoxazinas para o tratamento de doenças respiratórias
DK2172207T3 (da)	2013-04-08	Farmaceutisk sammensætning til behandling af diabetes og fremgangsmåde til fremstilling heraf
DK1734959T3 (da)	2010-03-08	Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter
DK1771426T3 (da)	2008-05-05	Diphenylaminsubstituererede salicylthiazolderivater og beslægtede forbindelser som phosphotyrosinphosphatase 1B (PTP1B) hæmmer til anvendelse som blodsukkersænkende aktive stoffer til behandling af diabetes
EP1905452A4 (en)	2012-02-15	ACTIVE AGENT FOR THE PREVENTION OR TREATMENT OF GLUCKOMEN
DK1750713T3 (da)	2013-02-11	Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner
DK1646378T3 (da)	2009-01-19	Farmaceutiske præparater omfattende ascorbinsyre til behandling af superinfektion med svamp og recidiv svamp
DE60331359D1 (de)	2010-04-01	Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
DK1919290T3 (da)	2014-04-22	Fremgangsmåder og produkter til behandling af sygdomme